N 1 -Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug-Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid.

MLA

Müller, Fabian, et al. “N 1 -Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug-Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid.” Clinical Pharmacology and Therapeutics, vol. 113, no. 5, May 2023, pp. 1070–79. EBSCOhost, https://doi.org/10.1002/cpt.2849.

APA

Müller, F., Hohl, K., Keller, S., Schmidt-Gerets, S., Deutsch, B., Schuler-Metz, A., Fromm, M. F., Stopfer, P., & Gessner, A. (2023). N 1 -Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug-Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid. Clinical Pharmacology and Therapeutics, 113(5), 1070–1079. https://doi.org/10.1002/cpt.2849

Chicago

Müller, Fabian, Kathrin Hohl, Sascha Keller, Sven Schmidt-Gerets, Birgit Deutsch, Annette Schuler-Metz, Martin F Fromm, Peter Stopfer, and Arne Gessner. 2023. “N 1 -Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug-Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid.” Clinical Pharmacology and Therapeutics 113 (5): 1070–79. doi:10.1002/cpt.2849.